Browsing: Wellness Tips

What’s behind the move:The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter

Curative Insurance Company on Tuesday announced a partnership with weight management company Wondr Health to expand weight and metabolic health support for its members

What are the best smoothies for weight loss? It’s a question we’ve been asked a lot lately, and we weren’t 100 percent sure of the answer—so we went directly to nutrition experts to get the skinny. Over a dozen RDs and doctors weighed in, and we were blown away by how similar their answers all…

After Tim McGraw and Faith Hill’s eldest daughter began using Ozempic to treat her symptoms for polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome, she shared how taking the weight loss drug led to poor body image

Amgen (NASDAQ:AMGN), the biotech heavyweight behind treatments for cancer, cardiovascular disease and other serious illnesses, gave investors another reason to cheer after posting a stronger-than-expected second quarter. Reuters reported revenue climbed 9% year over year to about $10.05 billion, while adjusted earnings landed at $6.29 per share, comfortably ahead of the $5.62 Wall Street consensus.…

Eli Lilly (NYSE:LLY | LLY Price Prediction) opened Wednesday’s session with a blowout second-quarter earnings report, sending shares sharply higher and cementing the drugmaker’s status as the only pharmaceutical company trading above a $1 trillion market cap. On a CNBC segment breaking down the release, anchor Joe Kernen walked viewers through the headline figures that…

ByMelissa Fleur Afshar Newsweek is a Trust Project member See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

The company’s obesity and diabetes franchise remained its biggest growth engine in the second quarter, with blockbuster GLP-1 drugs Mounjaro and Zepbound generating a combined $14.9 billion in revenue

Aug 5 (Reuters) – Sales of Eli Lilly’s Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk

to topclose Video This video is playing in picture-in-picture. On Air August 05, 2026 01:43 CLIP